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Precision radiogenomics: fusion biopsies to target tumour
habitats in vivo
Mireia Crispin-Ortuzar 1,2 and Evis Sala1,3
High-grade serous ovarian cancer lesions display a high degree of heterogeneity on CT scans. We have recently shown that regions
with distinct imaging profiles can be accurately biopsied in vivo using a technique based on the fusion of CT and ultrasound scans.
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In the last decade, the systematic, large-scale study of quantitative
features extracted from routine medical images has grown
exponentially due to increasing availability of larger datasets
and more powerful computational resources. This new way of
quantifying imaging data, known as radiomics, has been shown to
provide valuable prognostic information across cancer types.1,2
One of the main challenges for radiomics studies is their
interpretability; most of the time, the complexity of radiomics
features is such that correlating them with specific visual patterns
becomes almost impossible. As an alternative, integrative studies
have used data-driven techniques to correlate radiomics features
with different molecular or histopathological biomarkers in a more
recent subfield, known as radiogenomics.3
Radiogenomics studies are crucial for the overall success of
radiomics strategies. Not only are they essential to provide the
biological underpinning that will enable the development of
prospective clinical trials with radiomics biomarkers as end-points,
but they provide the foundations for one of the biggest promises of
the field—virtual biopsies. The idea of the virtual biopsy is that if the
correlation between a given radiomic signature and its underlying
molecular profile is sufficiently reliable, the signature itself can
be used as a surrogate, potentially obviating the need for invasive
tissue sampling procedures.4 This ability to strategically decide
whether taking a tissue biopsy is necessary or not could
be transformative for some of the most complex and aggressive
types of cancer, where radiomics features display striking hetero-
geneity even within a single lesion, defining so-called “habitats”.5 For
example, in high-grade serous ovarian cancer (HGSOC), our previous
work shows that patients with higher degrees of heterogeneity
between habitats on CT scans have significantly worse prognosis.6
Habitat-based heterogeneity in HGSOC lesions has been shown
to capture underlying differences in phylogenetic evolution7 and
T-cell infiltration8 in several pioneering studies, but the difficulty of
the experiments has significantly limited the number of patients
included. Crucially, these studies have so far focused on tissue
obtained from surgical tissue samples, which are easier to obtain
as the resected specimen is directly accessible. Even then, the
experiments have required the development of new technologies
based on 3D printing to enable accurate co-registration between
habitats and tumour tissue.9 The challenge of guiding biopsies to
habitats of interest in vivo, which is critical to understand the
evolution of the tumour microenvironment before and during
therapy, had so far been unexplored. One key obstacle is that
ultrasound guidance is the most common form of image-guided
biopsy, while radiomics habitats are typically defined on CT or
MRI scans.
We recently developed a study with the specific aim of
demonstrating the feasibility of a new technique to sample CT-
based habitats in vivo using ultrasound guidance in HGSOC
patients.10 The technology relies on the live co-registration of a
previously acquired CT scan and the ultrasound being used to
guide the biopsy. Once the co-registration has been achieved, the
habitats computed on the coordinate system of the CT scan can
be directly overlaid on top of the ultrasound image and used to
precisely and strategically guide the needle (Fig. 1).
Two main questions needed to be addressed to confirm the
feasibility of the technique; the integration into clinical pathways
and the accuracy of the result. We demonstrated the procedure
for six patients, obtaining biopsies from a pelvic lesion in two of
them, and from an omental lesion in four. We were able to extract
habitat maps for each of them using contrast-enhanced CT scans
acquired for disease staging as part of the standard of care. The
CT–ultrasound fusion was performed using the clinically approved
and commercially available US system from Canon Medical
Systems; as a result, the standard clinical biopsy protocols were
followed, with the only difference that the system was targeted to
a habitat within the lesion rather than just the lesion. The
procedure has now been integrated into our standard-of-care
pathway for US-guided biopsies in ovarian cancer, adding up to
15minutes to the standard biopsy procedure time. The segmenta-
tion and habitat computation are largely automated and do not
add any extra time for the patient. The fusion system relies on a
landmark-based system, and we were able to achieve co-
registration quality indicators of 8/10 to 10/10 in all six cases.
Ultrasound-guided biopsies in patients with suspected ovarian
carcinoma have been shown to be safe;11 we did not observe any
adverse events in this cohort.
To evaluate the accuracy of the co-registration for the tumour
specifically, we assessed the overlap between the manually-
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segmented contours of the lesions as seen on ultrasound and CT.
The average Dice similarity coefficient (DSC) of the pelvic lesions
was 0.78, which indicated a high co-registration accuracy and
therefore the adequacy of the method. Omental lesions, on the
other hand, had an average DSC of 0.36. Several factors may have
contributed to this lower accuracy: the omental deposits had a
smaller volume and had more flexible positions compared to the
larger, more fixed pelvic lesions. In addition, the anterior-posterior
axis has a higher degree of misregistration due to the local pressure
of the ultrasound probe. These results were encouraging and
suggest that with some improvements—such as patient tracker
systems that correct for local movements—the technique will be
able to provide accurate habitat guidance not only for pelvic
lesions but also for the more challenging omental metastases.
The ability to obtain habitat-guided biopsies routinely in HGSOC
patients has the potential to significantly impact the way we
understand and manage the disease. In general terms, guiding the
biopsies to specific habitats will allow us to maximise the
usefulness of the information obtained; in the long term, it may
even be possible to rely on entirely virtual, imaging-based biopsies
in some cases. Crucially, being able to track the evolution of the
heterogeneous composition of the disease via the combination of
habitat imaging and habitat-guided biopsies will make it possible
to assess response more precisely—which is vital for both the
drug development process and for clinical decision-making and
treatment adaptation. Our study bridges one of the key technical
barriers necessary to achieve this vision.
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Fig. 1 Schematic of the procedure used to obtain habitat-guided fusion biopsies. The steps are, from left to right: (1) segmentation of the
lesion on a CT scan (dashed line); (2) extraction of habitat maps, here represented by three different colours; and (3) real-time CT–ultrasound
co-registration. Figure reproduced from 10 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/).
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